Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
申请人:DermBiont, Inc.
公开号:US11040077B2
公开(公告)日:2021-06-22
Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.
MANESIS, NICK J.;GOODMAN, MURRAY, J. ORG. CHEM., 52,(1987) N 24, 5342-5349
作者:MANESIS, NICK J.、GOODMAN, MURRAY
DOI:——
日期:——
COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES
申请人:DermBiont, Inc.
公开号:US20200345799A1
公开(公告)日:2020-11-05
Disclosed herein are compositions and methods for using human-derived
Janthinobacterium lividum
. Compositions improve skin health. Methods may include applying human-derived
Janthinobacterium lividum
over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived
Janthinobacterium lividum
and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived
Janthinobacterium lividum
metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.
Synthesis of an isotopically labeled dilactam-bridged tetrapeptide